title: Lenalidomide as induction therapy before allogeneic stem cell transplantation in a patient with proliferative CMML-2 and del(5q) not involving the EGR1 locus.
authors.forename: U
authors.initials: U
authors.lastname: Platzbecker
authors.forename: B
authors.initials: B
authors.lastname: Mohr
authors.forename: M
authors.initials: M
authors.lastname: von Bonin
authors.forename: M
authors.initials: M
authors.lastname: Binder
authors.forename: J
authors.initials: J
authors.lastname: Schetelig
authors.forename: G
authors.initials: G
authors.lastname: Ehninger
authors.forename: M
authors.initials: M
authors.lastname: Bornhäuser
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D049109:Cell Proliferation; D002895:Chromosomes, Human, Pair 5; D003582:Cytogenetics; D051766:Early Growth Response Protein 1 / Q000235:genetics*; D017353:Gene Deletion; D006801:Humans; D000077269:Lenalidomide; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics* / Q000628:therapy*; D008297:Male; D012074:Remission Induction; D033581:Stem Cell Transplantation / Q000379:methods*; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013997:Time Factors; D014184:Transplantation, Homologous / Q000379:methods*
chemical_list: D000970:Antineoplastic Agents; C497325:EGR1 protein, human; D051766:Early Growth Response Protein 1; D013792:Thalidomide; D000077269:Lenalidomide